Know the Pros and Cons of Lecanemab for Alzheimer Disease
January 2026
You’ll hear buzz about a new Alzheimer med, lecanemab (Leqembi).
It’s an IV monoclonal antibody to treat mild cognitive impairment or mild dementia due to early Alzheimer disease. It’s NOT for dementia without amyloid plaque or more severe disease.
Lecanemab is being touted as “disease-modifying” because it reduces amyloid plaque...but it won’t reverse symptoms of Alzheimer disease.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive